- Barrons.com•6 hours ago
Everyone who is everyone wants to buy Medivation (MDVN). Sanofi (SNY) has bid more than $9 billion for the biotech company, while Medivation is often presented as a cure for what ails Gilead Sciences (GILD). Pfizer (PFE), and Amgen (AMGN) have also been mentioned as potential suitors.
Yesterday, Gilead Sciences (GILD) announced better-than-forecast earnings but full-year sales guidance that fell short of analyst predictions, causing its shares to tumble. As result, expectations for ...
After hours: 62.50-0.05 (-0.08%) as of 4:52 PM EDT
|Bid||62.30 x 500|
|Ask||62.50 x 200|
|52wk Range||26.41 - 63.35|
|Day's Range||62.27 - 63.01|
|Avg Vol (3m)||2,749,179|
As of 4:00 PM EDT. Market closed.